title: Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells.
abstract: The CX3C chemokine fractalkine (CX3CL1) exists as both a membrane-bound form promoting firm cell-cell adhesion and a soluble form chemoattracting leukocytes expressing its receptor CX3CR1. When adenoviral vector expressing mouse fractalkine (AdFKN) was transduced to the tumor cells, fractalkine was expressed as both membrane-bound form on the tumor cells and soluble form in the supernatant in vitro. Intratumoral injection of AdFKN (1 x 10(9)PFU/tumor) into C26 and B16F10 tumors resulted in marked reduction of tumor growth compared to control (C26: 86.5%, p<0.001; B16F10: 85.5%, p<0.001). Histological examination of tumor tissues revealed abundant infiltration of NK cells, dendritic cells, and CD8(+) T lymphocytes 3 and/or 6 days after treatment with AdFKN. Splenocytes from mice treated by AdFKN developed tumor-specific cytotoxic T cells, and thereby protected from rechallenging with parental tumor cells. Antitumor effects by AdFKN were completely abrogated in both NK cell-depleted mice and CD8(-/-) mice, and partially blocked in CD4(-/-) mice. These data indicated that fractalkine mediates antitumor effects by both NK cell-dependent and T cell-dependent mechanisms. This study suggests that fractalkine can be a suitable candidate for immunogene therapy of cancer because fractalkine induces both innate and adaptive immunity.
authors.affiliation: Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan.
authors.forename: Hong
authors.initials: H
authors.lastname: Xin
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Sita
authors.initials: S
authors.lastname: Andarini
authors.forename: Shinya
authors.initials: S
authors.lastname: Ohkouchi
authors.forename: Takuji
authors.initials: T
authors.lastname: Suzuki
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Nukiwa
authors.lastname: Huqun
authors.forename: Koichi
authors.initials: K
authors.lastname: Hagiwara
authors.forename: Tasuku
authors.initials: T
authors.lastname: Honjo
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Saijo
mesh_terms: D000818:Animals; D015153:Blotting, Western; D045744:Cell Line, Tumor; D054428:Chemokine CX3CL1; D020523:Chemokines, CX3C / Q000235:genetics / Q000276:immunology*; D005434:Flow Cytometry; D015316:Genetic Therapy; D007694:Killer Cells, Natural / Q000276:immunology*; D016131:Lymphocyte Subsets / Q000276:immunology*; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D009369:Neoplasms / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology*; D014161:Transduction, Genetic
chemical_list: D054428:Chemokine CX3CL1; D020523:Chemokines, CX3C; C515539:Cx3cl1 protein, mouse; D008565:Membrane Proteins